脓毒症性心肌病的血管活性药物选择  

Selection of vasoactive agents in septic cardiomyopathy

作　　者：刘一娜[1] 马晓春[1] Liu Yina;Ma Xiaochun(Department of Critical Care Medicine,the First Affiliated Hospital of China Medical University,Shenyang 110001,China)

机构地区：[1]中国医科大学附属第一医院重症医学科,辽宁沈阳110001

出　　处：《中华重症医学电子杂志》2020年第2期128-131,共4页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

摘　　要：脓毒症性心肌病是脓毒症导致的急性心功能障碍综合征,与冠状动脉阻塞所致缺血无明显关联,其以心室扩张、心肌收缩减弱、心功能损害具有可逆性为特征,诊断和治疗措施尚不明确。一般认为脓毒症性心肌病的治疗策略与未合并心肌病的脓毒症并无明显不同,血管活性药物的选择可参照脓毒症、感染性休克的临床研究及指南推荐意见实施,个体化治疗策略还有待高质量的临床研究数据提供。Septic cardiomyopathy is an acute syndrome of cardiac dysfunction that is unrelated to cardiac ischemia in patients with sepsis.It is characterized by ventricular dilation,myocardial contraction weakening,and reversible cardiac dysfunction.There have been no standards for the diagnosis and therapy of septic cardiomyopathy,and the treatment strategy currently used for septic cardiomyopathy is the same as that for sepsis without cardiomyopathy.When selecting vasoactive agents,the recommendations from sepsis guidelines should be taken into account.Further clinical research of individualized treatment for septic cardiomyopathy is necessary.

关 键 词：脓毒症 心肌疾病 血管活性药物 儿茶酚胺类 血管升压素类 β受体阻滞剂 

分 类 号：R542.2[医药卫生—心血管疾病] R459.7[医药卫生—内科学]